[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

YU13200A - Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja - Google Patents

Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja

Info

Publication number
YU13200A
YU13200A YU13200A YU13200A YU13200A YU 13200 A YU13200 A YU 13200A YU 13200 A YU13200 A YU 13200A YU 13200 A YU13200 A YU 13200A YU 13200 A YU13200 A YU 13200A
Authority
YU
Yugoslavia
Prior art keywords
intermediates
compounds
preparing anti
cancer compounds
hyperproliferate
Prior art date
Application number
YU13200A
Other languages
English (en)
Inventor
Richard Shelton Lehner
Timothy Norris
Dinos Paul Santafianos
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU13200A publication Critical patent/YU13200A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Metallurgy (AREA)
  • Mechanical Engineering (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Predmetni pronalazak se odnosi na postupke i intermedijere za dobijanje jedinjenja formule I i njihovih farmaceutski prihvatljivih soli i solvata, kao i na strukturno slična jedinjenja, gde R1, R2 i R15 su kao što je definisano ovde. Gornja jedinjenja su primenljiva u tretiranju hiperproliferativnih poremećaja, takvih kao što su kanceri kod sisara.[The subject matter of the invention refers to the process es and intermediates for obtaining of compounds of the formula I and their pharmaceutically acceptable salts and solvates as well as the structurally similar compounds where R1, R2 and R15 are as defined here. The above mentioned compounds are applicable in the treatment of the hyperproliferate disturbances, such as cancers with mammals.
YU13200A 1999-03-31 2000-03-03 Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja YU13200A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
YU13200A true YU13200A (sh) 2002-10-18

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
YU13200A YU13200A (sh) 1999-03-31 2000-03-03 Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja

Country Status (50)

Country Link
US (1) US6476040B1 (sh)
EP (1) EP1044969B1 (sh)
JP (2) JP3420549B2 (sh)
KR (2) KR100430210B1 (sh)
CN (2) CN100351242C (sh)
AP (2) AP1655A (sh)
AR (1) AR018705A1 (sh)
AT (1) ATE348098T1 (sh)
AU (2) AU781402B2 (sh)
BG (1) BG65194B1 (sh)
BR (1) BRPI0001486B8 (sh)
CA (2) CA2302965C (sh)
CO (1) CO5160273A1 (sh)
CR (1) CR6165A (sh)
CZ (1) CZ299426B6 (sh)
DE (1) DE60032275T2 (sh)
DK (1) DK1044969T3 (sh)
DZ (1) DZ3030A1 (sh)
EA (3) EA005561B1 (sh)
EE (1) EE04589B1 (sh)
EG (1) EG22506A (sh)
ES (1) ES2278578T3 (sh)
GE (1) GEP20022653B (sh)
GT (1) GT200000037A (sh)
HK (1) HK1029790A1 (sh)
HR (1) HRP20000182B1 (sh)
HU (1) HU227698B1 (sh)
ID (1) ID25427A (sh)
IL (2) IL135245A0 (sh)
IS (1) IS2468B (sh)
MA (1) MA25087A1 (sh)
MY (1) MY136270A (sh)
NO (2) NO321952B1 (sh)
NZ (2) NZ512818A (sh)
OA (1) OA11335A (sh)
PA (1) PA8491901A1 (sh)
PE (1) PE20001599A1 (sh)
PL (1) PL339330A1 (sh)
PT (1) PT1044969E (sh)
RS (1) RS49836B (sh)
SG (2) SG115536A1 (sh)
SK (1) SK287339B6 (sh)
SV (1) SV2002000047A (sh)
TN (1) TNSN00064A1 (sh)
TR (1) TR200000837A2 (sh)
TW (1) TW553939B (sh)
UA (2) UA70928C2 (sh)
UY (1) UY26086A1 (sh)
YU (1) YU13200A (sh)
ZA (1) ZA200001586B (sh)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
RU2378268C2 (ru) 2003-09-16 2010-01-10 Астразенека Аб Производные хиназолина в качестве ингибиторов тирозинкиназы
PT2210607E (pt) 2003-09-26 2012-01-31 Exelixis Inc N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolina-4-ilpropil)oxi]quinolina-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida para o tratamento do cancro
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
GEP20084551B (en) * 2004-05-06 2008-11-25 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
AU2006217692A1 (en) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel combinational use of sulfonamide compound
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007052849A1 (ja) * 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008001956A1 (fr) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
EP2054393A1 (en) 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
KR20090108086A (ko) 2007-01-19 2009-10-14 에자이 알앤드디 매니지먼트 가부시키가이샤 췌장암 치료용 조성물
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
ES2573931T3 (es) * 2007-02-21 2016-06-13 Natco Pharma Limited Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
EP2139868B1 (en) 2007-04-04 2015-07-29 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
EP2162444B1 (en) 2007-07-11 2014-06-04 Hetero Drugs Limited An improved process for the preparation of erlotinib hydrochloride
WO2009025876A2 (en) * 2007-08-23 2009-02-26 Plus Chemicals, S.A. Crystalline forms of erlotinib hcl and formulations thereof
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
CA2713930A1 (en) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
KR20110005828A (ko) * 2008-03-28 2011-01-19 콘서트 파마슈티컬즈, 인크. 퀴나졸린 유도체 및 치료방법
US20100004449A1 (en) * 2008-07-07 2010-01-07 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2499118A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
JP5898074B2 (ja) 2010-06-25 2016-04-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
WO2012028861A1 (en) 2010-07-23 2012-03-08 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
EP1110953B1 (en) * 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
NZ508154A (en) 1998-04-29 2003-07-25 Osi Pharm Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Also Published As

Publication number Publication date
EA005561B1 (ru) 2005-04-28
EA004654B1 (ru) 2004-06-24
DE60032275D1 (de) 2007-01-25
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
NO20001648D0 (no) 2000-03-30
UA70928C2 (uk) 2004-11-15
CR6165A (es) 2008-10-10
CA2302965A1 (en) 2000-09-30
AU2005201494A1 (en) 2005-05-05
DK1044969T3 (da) 2007-04-23
KR100430209B1 (ko) 2004-05-03
CZ299426B6 (cs) 2008-07-23
PA8491901A1 (es) 2001-12-14
CA2427221A1 (en) 2000-09-30
CN1276370A (zh) 2000-12-13
BRPI0001486B1 (pt) 2019-01-29
EA200000274A2 (ru) 2000-10-30
GEP20022653B (en) 2002-03-25
DE60032275T2 (de) 2007-07-12
SK287339B6 (sk) 2010-07-07
SK4442000A3 (en) 2000-10-09
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
CA2427221C (en) 2008-09-16
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
ZA200001586B (en) 2001-10-01
KR20020084903A (ko) 2002-11-13
JP2003176274A (ja) 2003-06-24
US6476040B1 (en) 2002-11-05
HUP0001353A2 (hu) 2001-05-28
SV2002000047A (es) 2002-01-23
EP1044969B1 (en) 2006-12-13
ATE348098T1 (de) 2007-01-15
EA005892B1 (ru) 2005-06-30
UA80955C2 (en) 2007-11-26
NZ503683A (en) 2001-09-28
CN1699350A (zh) 2005-11-23
NO20001648L (no) 2000-10-02
JP3420549B2 (ja) 2003-06-23
CZ20001155A3 (cs) 2001-03-14
EE200000255A (et) 2000-12-15
AP1265A (en) 2004-03-26
MA25087A1 (fr) 2000-10-01
JP2000290262A (ja) 2000-10-17
BG104278A (en) 2001-08-31
ES2278578T3 (es) 2007-08-16
HK1029790A1 (en) 2001-04-12
DZ3030A1 (fr) 2004-03-27
TR200000837A2 (tr) 2000-11-21
ID25427A (id) 2000-10-05
BRPI0001486B8 (pt) 2021-05-25
CA2302965C (en) 2004-02-17
KR100430210B1 (ko) 2004-05-03
HU227698B1 (en) 2011-12-28
PL339330A1 (en) 2000-10-09
PT1044969E (pt) 2007-05-31
AR018705A1 (es) 2001-11-28
EA200000274A3 (ru) 2003-02-27
IS5411A (is) 2000-10-02
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
GT200000037A (es) 2001-09-21
SG115536A1 (en) 2005-10-28
BR0001486A (pt) 2001-05-02
OA11335A (en) 2003-12-10
AU2005201494B2 (en) 2008-02-07
AU781402B2 (en) 2005-05-19
SG121687A1 (en) 2006-05-26
PE20001599A1 (es) 2001-01-18
IS2468B (is) 2008-12-15
BG65194B1 (bg) 2007-06-29
EE04589B1 (et) 2006-02-15
EP1044969A3 (en) 2000-11-29
MY136270A (en) 2008-09-30
JP4074509B2 (ja) 2008-04-09
KR20010014658A (ko) 2001-02-26
UY26086A1 (es) 2000-10-31
CN1215061C (zh) 2005-08-17
HU0001353D0 (en) 2000-06-28
EA200201244A1 (ru) 2003-04-24
HUP0001353A3 (en) 2002-01-28
EA200201245A1 (ru) 2003-04-24
RS49836B (sr) 2008-08-07
AP1655A (en) 2006-09-01
IL135245A0 (en) 2001-05-20
TW553939B (en) 2003-09-21
CO5160273A1 (es) 2002-05-30
NZ512818A (en) 2003-01-31
NO20054715L (no) 2000-10-02
NO321952B1 (no) 2006-07-24
HRP20000182A2 (en) 2001-04-30
CN100351242C (zh) 2007-11-28

Similar Documents

Publication Publication Date Title
YU13200A (sh) Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
MY127181A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
RS20050180A (en) Novel benzoimidazole derivatives useful as antiproliferative agensts
NL350075I2 (sh)
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
NZ519241A (en) Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
HK1052940A1 (en) Synthetic methods for aplidine and new antitumoralderivatives, methods of making and using them
HK1045526A1 (en) Sapogenin derivatives and their use in the treatment of cognitive dysfunction.
DE69907419D1 (en) Antitumorwirkstoffe
IL135825A0 (en) Use of mirtazapine for treating sleep apneas
WO2002026720A3 (en) PIPERAZINE BASED INHIBITORS OF FACTOR Xa
HK1055304A1 (en) Tricyclic imidazopyridines
TNSN02096A1 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
IL162058A0 (en) Hexacyclic compounds
MX9601163A (es) Nuevos compuestos derivados de cromeno.
NZ233618A (en) Optionally heterocyclic substituted pyrrolidone derivatives and pharmaceutical compositions
DE60044804D1 (de) Acylderivate des 4-demethylpenclomedins, verwendung und zubereitung derselben
MY120806A (en) Improved process for preparing pharmaceutically valuable norbenzomorphane derivatives.